SOURCE: PropThink, LLC

September 27, 2013 09:15 ET

PropThink to Host Special Conference Call With Tekmira CEO

Investors Are Invited to Dial in and Participate in an Exclusive Conference Call With Tekmira Pharmaceuticals CEO Dr. Mark Murray; Free Registration on PropThink.com Is Required to Join

NEW YORK, NY--(Marketwired - Sep 27, 2013) - PropThink.com ("PropThink"), a leading healthcare-focused provider of investment research and analysis, will host an interview and investor Q&A conference call with Dr. Mark Murray, Chief Executive Officer and President of Tekmira Pharmaceuticals (NASDAQ: TKMR) (TSX: TKM), on Thursday, October 3, 2013 at 3:00PM ET.

The call is open to all investors who complete a free registration on PropThink.com. Further instructions are available by visiting PropThink.com/TekmiraCall or by clicking here.

Why We're Interviewing Tekmira

Despite underperforming the broader biotech sector for much of 2013, Tekmira Pharmaceuticals has one of the leading delivery mechanisms for RNAi-based therapeutics in addition to a growing pipeline of proprietary therapeutic candidates. With investor interest in RNAi and siRNA rapidly increasing, PropThink believes that Tekmira provides an interesting investment opportunity given its low relative valuation, strong balance sheet, and attractive technology platform.

Tekmira's lipid nanoparticle technology (LNP) for RNAi and siRNA delivery is a compelling approach in the development of highly targeted therapeutics. The company's LNP technology enables a number of leading RNAi drug candidates in development for oncology, infectious diseases, and orphan indications. Tekmira's lead internal candidate, TKM-PLK1, utilizes LNP delivery to target the polo-like kinase 1 in some gastrointestinal cancers, and a Phase I/II clinical trial began in August of this year. Furthermore, a high profile orphan drug developed by a Tekmira partner recently garnered significant attention from the capital markets and relies entirely on the LNP delivery platform. Tekmira operates the only government-funded Ebola virus drug development program in the U.S. and plans to move a new formulation into the clinic early next year. Following the settlement of long-standing litigation with a partner in 2012, the company is well financed and strategically positioned to capitalize on its wholly owned platform technology.

How To Participate

1. Investors interested in participating in this PropThink-hosted event will need to register by visiting PropThink.com/TekmiraCall or by clicking here. Registration is open to all investors free of charge.

2. Registrants will receive a confirmation email with dial-in instruction 24 hours prior to the conference call. Participating investors will have the ability to ask Dr. Mark Murray questions following the interview portion of the call -- the operator will provide instructions on how to join the question queue during the call.

Questions about the event can be directed to editor@propthink.com in advance.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically complicated companies and equities that are grossly over- or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more, follow us on Twitter or visit us at http://www.propthink.com. In addition, PropThink is offering investors 30 days of free access to a premium intelligence service designed to empower individual investors by providing actionable, timely, and accurate research on companies and investment opportunities in the healthcare sector.